Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

229.34B

Market cap229.34B

Price-Earnings ratio

14.16

Price-Earnings ratio14.16

Dividend yield

2.49%

Dividend yield2.49%

Average volume

31.24M

Average volume31.24M

High today

$50.53

High today$50.53

Low today

$49.15

Low today$49.15

Open price

$50.06

Open price$50.06

Volume

10.94M

Volume10.94M

52 Week high

$93.80

52 Week high$93.80

52 Week low

$43.08

52 Week low$43.08

NVO News

TipRanks 8h

Canaccord cuts Hims & Hers target, says legal risk may be priced in

Canaccord lowered the firm’s price target on Hims & Hers (HIMS) to $30 from $68 and keeps a Buy rating on the shares after Novo Nordisk (NVO) filed a lawsuit ag...

TipRanks 8h

Novo Nordisk Discloses Executive Share Sale to Cover Tax on Long-Term Incentive Shares

Novo Nordisk ( (NVO) ) has issued an announcement. On 9 February 2026, Novo Nordisk Executive Vice President for R&D and Chief Scientific Officer Martin Holst...

Sherwood News 10h

Hims built a boundary-pushing health business. Now the legal risks are catching up.

Hims is close to trading as if it never began selling GLP-1s. Hims & Hers aired its second Super Bowl commercial on Sunday, questioning a healthcare system it...

Analyst ratings

53%

of 34 ratings

Buy

52.9%

Hold

35.3%

Sell

11.8%

More NVO News

TipRanks 13h

‘Blatant Attack’: HIMS Stock Plunges as Novo Lawsuit Triggers Analyst Price Target Cuts

Shares of Hims & Hers Health (HIMS) fell about 16% on Monday, extending last week’s losses following a regulatory crackdown on its non-FDA-approved compounds. T...

Simply Wall St 19h

Novo Nordisk Lawsuit Tests Obesity Drug Patents And Valuation Upside

Novo Nordisk (NYSE:NVO) has filed a lawsuit against Hims & Hers, alleging patent infringement tied to compounded oral semaglutide products. The case centers on...

The Motley Fool 21h

Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit

Today, Feb. 9, 2026, investors are reevaluating Hims & Hers after it pulled its weight-loss pill, facing legal action and FDA scrutiny. Expand NYSE : HIMS Hims...

Nasdaq 22h

Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast?

Key Points On Friday, the U.S. Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 ingredients in compounded drugs not approved...

Cheddar 23h

Novo Nordisk Sues Hims Over Copycat Wegovy

Novo Nordisk is suing telehealth company Hims & Hers, accusing it of illegally mass marketing cheaper, unapproved compounded versions of Wegovy....

Nasdaq 24h

Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment?

Key Points Eli Lilly has been a growth beast and its top line may soar by as much as 27% this year. Novo Nordisk is bracing for a potential double-digit decli...

Benzinga 1d

FDA Uncertainty Pushes Analyst To Lower Hims & Hers Forecast

• Hims & Hers Health stock is at significant support. What’s pressuring HIMS? What Happened Last Thursday, Hims & Hers Health announced an expansion of its we...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.